BenzingaAugust 4, 2026 at 10:11 AM NYlast month

Mizuho Maintains Outperform on Biogen, Raises Price Target to $241

Mizuho analyst Salim Syed maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Companies in This Story